Abstract:
|
This project aimed to demonstrate the effect of probiotic Lactobacillus pentosus S-PT84 and prebiotic isomaltodexrin (IMD) on disordered gut microflora in lipopolysaccharide (LPS)- induced low-grade chronic inflammatory mouse model. LPS administration to mice leads to increased intestinal permeability and elevated LPS, which ultimately causes metabolic endotoxemia and low-grade inflammation. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to determine quantitative changes of Bifidobacteria bifidum, Lactobacillus casei, Escherichia coli, Clostridium difficile, and Bacteroides fragilis. Pre-treatment with L. pentosus S-PT84 or IMD increased the relative population expression of B. bifidum, L. casei, and B. fragilis, and decreased the relative population expression of E. coli and C. difficile. Moreover, probiotic L. pentosus S-PT84 and prebiotic IMD alleviated the disturbance of gut microflora in LPS-treated mice as the number of B. bifidum, L. casei, and B. fragilis increased, and E. coli and C. difficile decreased when compared to LPS-treated mice. The analysis of short chain fatty acids (SCFAs) further supported that the concentrations of acetic and butyric acids were positively correlated with probiotic L. pentosus S-PT84 and prebiotic IMD, as well as the number of beneficial bacteria. This study elucidates that probiotic L. pentosus S-PT84 and prebiotic IMD are potent nutraceuticals, beneficial for gut microbiota improvement. |